Review Article
TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
Table 4
Meta-analysis results for the occurrence of adverse events in uncontrolled experiments.
| | Outcomes | Any grade | | | Methods | Trials | Rate (95% CI) | | | Methods | Trials | Rate (95% CI) | | |
| | Nonhematological | | | | | | | | | | | | Vomiting | TAS-102 | 5 | 0.10 (0.04-0.16) | 57.60% | <0.001 | TAS-102 | 3 | 0.02 (-0.00-0.05) | 0% | 0.059 | | TAS-102+B | 2 | 0.21 (0.12-0.30) | 0% | <0.001 | | | | | | | Nausea | TAS-102 | 6 | 0.27 (0.17-0.38) | 81.00% | <0.001 | TAS-102 | 2 | 0.01 (-0.01-0.04) | 0% | 0.251 | | TAS-102+B | 2 | 0.58 (0.47-0.69) | 0% | <0.001 | TAS-102+B | 2 | 0.07 (0.01-0.12) | 0% | 0.021 | | Asthenia | TAS-102 | 8 | 0.36 (0.25-0.47) | 86.20% | <0.001 | TAS-102 | 6 | 0.05 (0.03-0.08) | 0% | <0.001 | | TAS-102+B | 2 | 0.56 (0.40-0.72) | 53.60% | <0.001 | TAS-102+B | 1 | 0.03 (-0.03-0.09) | | 0.31 | | Decreased appetite | TAS-102 | 4 | 0.25 (0.13-0.37) | 75.90% | <0.001 | TAS-102 | 1 | 0.10 (-0.01-0.21) | NA | 0.068 | | TAS-102+B | 1 | 0.66 (0.49-0.82) | NA | <0.001 | TAS-102+B | 1 | 0.06 (-0.02-0.15) | NA | 0.144 | | Diarrhea | TAS-102 | 7 | 0.13 (0.07-0.19) | 76.00% | <0.001 | TAS-102 | 5 | 0.06 (0.01-0.12) | 75.30% | 0.023 | | TAS-102+B | 2 | 0.22 (0.12-0.31) | 1.90% | <0.001 | TAS-102+B | 1 | 0.03 (0.00-0.05) | NA | 0.043 | | Abdominal pain | TAS-102 | 3 | 0.17 (0.04-0.30) | 72.30% | 0.012 | | | | | | | Fever | TAS-102 | 4 | 0.06 (0.02-0.10) | 0% | 0.001 | TAS-102 | 1 | 0.10 (-0.01-0.21) | NA | 0.068 | | TAS-102+B | 1 | 0.18 (0.07-0.30) | NA | 0.002 | TAS-102+B | 1 | 0.05 (-0.02-0.11) | NA | 0.148 | | Hematological | | | | | | | | | | | | Neutropenia | TAS-102 | 7 | 0.55 (0.43-0.67) | 84.70% | <0.001 | TAS-102 | 8 | 0.30 (0.26-0.35) | 26.50% | <0.001 | | TAS-102+B | 2 | 0.67 (0.57-0.78) | 0% | <0.001 | TAS-102+B | 2 | 0.10 (0.01-0.20) | 47.80% | 0.029 | | Anemia | TAS-102 | 6 | 0.49 (0.18-0.80) | 98.70% | 0.002 | TAS-102 | 8 | 0.07 (0.05-0.09) | 4.50% | <0.001 | | TAS-102+B | 2 | 0.89 (0.82-0.96) | 0% | <0.001 | TAS-102+B | 2 | 0.09 (0.03-0.16) | 0% | 0.005 | | Leukopenia | TAS-102 | 2 | 0.66 (0.58-0.74) | 0% | <0.001 | TAS-102 | 2 | 0.06 (0.03-0.09) | 0% | <0.001 | | TAS-102+B | 1 | 0.72 (0.56-0.87) | NA | <0.001 | TAS-102+B | 1 | 0.47 (0.30-0.64) | NA | <0.001 | | Febrile neutropenia | TAS-102 | 2 | 0.09 (-0.02-0.21) | 74.90% | 0.113 | TAS-102 | 3 | 0.08 (0.02-0.14) | 49.70% | 0.012 | | Thrombocytopenia | TAS-102 | 6 | 0.26 (0.12-0.39) | 93.7% | <0.001 | TAS-102 | 5 | 0.01 (0.00-0.02) | 8.60% | 0.014 | | TAS-102+B | 2 | 0.37 (0.21-0.53) | 0% | <0.001 | TAS-102+B | 2 | 0.06 (0.01-0.12) | 30.40% | 0.022 |
|
|
